Hubei Jumpcan Pharmaceutical: Higher margins and adjusted profit offset softer 9M revenue and volatile investment resultsQuartr·Oct 29, 2026 at 08:46 AM600566+0.44%
AKESO grants commercialization rights for Yixinning, receiving a licensing fee of 80 million RMBAASTOCKS·Feb 3, 2026 at 03:42 PM516820-0.57%159849-1.64%
With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibitedWallstreetcn·Jan 27, 2026 at 10:41 AM512290-1.79%159929-0.99%
JUMPCAN's subsidiary has obtained the drug registration certificate for lidocaine gel patchesZhitong·Sep 16, 2025 at 08:35 AM600566+0.44%
Zhitong A-share lock-up release overview | September 8Zhitong·Sep 8, 2025 at 01:01 AM600526-0.68%000762-1.84%
Cao Fei intends to acquire JUMPCAN, and the supervision situation in the second quarter has been goodZhitong·Sep 3, 2025 at 08:26 AM600566+0.44%
JUMPCAN released its performance for the first half of the year, with a net profit attributable to the parent company of 724 million yuan, a year-on-year decrease of 45.87%Zhitong·Aug 22, 2025 at 12:57 PM600566+0.44%
JUMPCAN established a medical technology company in HainanZhitong·Aug 1, 2025 at 05:56 AM600566+0.44%
JUMPCAN disclosed the results of Cao Fei's tender offer and will resume trading tomorrowZhitong·Jul 20, 2025 at 09:06 AM600566+0.44%
JUMPCAN: The cooperative product Marcilosavir tablets have obtained the drug registration certificateZhitong·Jul 20, 2025 at 07:56 AM600566+0.44%
JUMPCAN: Cao Fei's tender offer period expires, stock suspended on July 18Zhitong·Jul 17, 2025 at 08:52 AM600566+0.44%
JUMPCAN: Received the acceptance notice for the pediatric constipation granules medicationZhitong·Jul 7, 2025 at 07:35 AM600566+0.44%
Changjiang Securities: JUMPCAN has long-term stable development, initiating a "Buy" ratingZhitong·Jun 23, 2025 at 07:38 AM600566+0.44%
Huafu Securities: The Chinese medicine sector is expected to improve quarter by quarter in Q2-3 of 2025. Pay attention to the possibility of including innovative drug varieties in this year's medical insuranceZhitong·Jun 23, 2025 at 03:33 AM688658-4.02%600566+0.44%
